In a phase II study to assess the safety and tolerability of nivolumab administered alone or in combination with ipilimumab or relatlimab, alterations in T cell receptor clonotypes and changes in transcription profiles in CD8 T cells from blood and tumor following monotherapy and combination immune checkpoint blockade were analysed in treatment-naïve patients with HNSCC [42]. The gene discussed is CD8A; the disease is neoplasm.